

REVIEW

Open Access



# Phospholipase A<sub>2</sub> in skin biology: new insights from gene-manipulated mice and lipidomics

Makoto Murakami<sup>1,2</sup>, Kei Yamamoto<sup>3,4</sup> and Yoshitaka Taketomi<sup>1\*</sup>

## Abstract

The skin represents one of the tissues that are most profoundly influenced by alterations in the quality of lipids (lipoquality). Lipids not only constitute cellular membranes, but also serve as bioactive lipid mediators and essential components of the skin barrier. Phospholipase A<sub>2</sub> (PLA<sub>2</sub>) enzymes supply fatty acids and lysophospholipids from membrane phospholipids, thereby variably affecting cutaneous homeostasis. Accordingly, perturbation of particular PLA<sub>2</sub>-driven lipid pathways can be linked to various forms of skin disease. In this review article, we highlight the roles of several PLA<sub>2</sub> subtypes in cutaneous pathophysiology, as revealed by transgenic/knockout studies in combination with comprehensive lipidomics. We focus mainly on secreted PLA<sub>2</sub> group IIF (sPLA<sub>2</sub>-IIF), which is associated with epidermal hyperplasia through mobilization of a unique lipid metabolite. We also address the distinct roles of sPLA<sub>2</sub>-IIE in hair follicles and sPLA<sub>2</sub>-IID in lymphoid immune cells that secondarily affect cutaneous inflammation, and provide some insights into species differences in sPLA<sub>2</sub>s. Additionally, we briefly overview the patatin-like phospholipase PNPLA1, which belongs to the Ca<sup>2+</sup>-independent PLA<sub>2</sub> (iPLA<sub>2</sub>) family, as a key regulator of skin barrier function through catalysis of a unique non-PLA<sub>2</sub> reaction. These knowledges on lipid metabolism driven by various PLA<sub>2</sub> subtypes will open novel opportunities for translated studies toward diagnosis and therapy of human skin diseases.

**Keywords:** Knockout mouse, Lipid mediator, Lipidomics, Phospholipase A<sub>2</sub>, Skin

## Background

The skin consists of the outer epidermis, beneath which are the dermis and subcutaneous tissue. Epidermal keratinocytes undergo a tightly regulated program of proliferation and differentiation leading to formation of the stratified epidermis, which consists of four layers including the stratum basale (SB), the stratum spinosum (SS), the stratum granulosum (SG), and the stratum corneum (SC) from the inside to the outside. For survival in a dry terrestrial environment, the epidermis constitutes a life-sustaining skin barrier, which not only prevents water loss (inside-out barrier), but also protects against invasion of environmental substances or microorganisms (outside-in barrier) [1]. In the uppermost SC, corneocytes are

embedded in a lipid-rich extracellular matrix that forms lamellar membranes composed of ceramides, cholesterol, and fatty acids in a mildly acidic environment [2]. The epidermis also has immunologic functions, protecting the skin from ultraviolet damage via pigmentation of melanocytes and from external harmful stimuli by releasing various bioactive factors such as cytokines, chemokines, DAMPs (danger-associated molecular patterns), and lipid mediators, which relay signals to specialized immune cells residing in the epidermis and dermis [3].

Another important component of the skin is the hair follicle, whose morphogenesis is regulated by interactions between epidermal keratinocytes committed to hair follicle differentiation and dermal fibroblasts committed to formation of the dermal papilla of developing hair follicles [4]. These epithelial-mesenchymal interactions culminate in the formation of the hair shaft, which is surrounded by the multilayered inner root sheath and outer root sheath, the latter comprising an outermost

\* Correspondence: [taketomiys@m.u-tokyo.ac.jp](mailto:taketomiys@m.u-tokyo.ac.jp)

<sup>1</sup>Laboratory of Microenvironmental and Metabolic Health Science, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan  
Full list of author information is available at the end of the article



concentric layer of keratinocytes. Hair follicles undergo repeated cycles of growth (anagen), regression (catagen), and rest (telogen) during their life span, representing one of the most regenerative organs in the body. Within the apex of the follicle are sebaceous glands, which produce sebum. The adipocyte layer within the hypodermis also constitutes a significant compartment of the skin, contributing to hair follicle activation [5], skin regeneration [6], and cold-induced adaptive thermogenesis [7].

Lipids play fundamental roles in skin physiology and pathology. Dysregulated production of polyunsaturated fatty acid (PUFA)- or lysophospholipid-derived lipid mediators can be linked to skin disorders including alopecia, inflammation, and cancer. For instance, arachidonic acid (AA;  $\omega$ 6 C20:4)-derived lipid mediators such as prostaglandins (PGs) and leukotrienes (LTs) have diverse roles in immune responses and keratinocyte activation [8, 9], eicosapentaenoic acid (EPA;  $\omega$ 3 C20:5)- or docosahexaenoic acid (DHA;  $\omega$ 3 C22:6)-derived resolvins attenuate skin immune responses [10, 11], and lysophosphatidic acid (LPA) controls hair homeostasis [12, 13]. Apart from these signaling lipids, linoleic acid (LA;  $\omega$ 6 18:2), by far the most abundant PUFA in the epidermis, is esterified to the  $\omega$ -hydroxyl group of ultra-long chain fatty acids in ceramides, thus forming  $\omega$ -*O*-acylceramide, a structural lipid that is essential for skin barrier function [14]. Fatty acids have also been proposed to be important for SC acidification [15].

Release of fatty acids and lysophospholipids from glycerophospholipids (phospholipids hereafter) is catalyzed by phospholipase A<sub>2</sub> (PLA<sub>2</sub>) enzymes, which are classified into several families as shown in Table 1 [16]. Until recently, however, it has remained obscure as to which PLA<sub>2</sub> subtype(s) is important in the skin, which lipid species serve as the substrates and products for the PLA<sub>2</sub>(s), and how the PLA<sub>2</sub>-driven lipid metabolites affect skin pathophysiology. In this review, we highlight the distinct roles of several secreted PLA<sub>2</sub>s (sPLA<sub>2</sub>s) and the patatin-like phospholipase PNPLA1, whose functions have been revealed by recent studies using gene-manipulated (transgenic and knockout) mice in combination with mass spectrometry-based analytical techniques referred to collectively as lipidomics. Importantly, these enzymes are linked to unique lipid pathways distinct from canonical AA metabolism. The localizations and functions of particular PLA<sub>2</sub>s in the skin, as described in this review, are summarized in Fig. 1.

### sPLA<sub>2</sub>-IIF, an epidermal sPLA<sub>2</sub>

The sPLA<sub>2</sub> family consists of 11 isoforms with distinct substrate specificities and tissue distributions [17, 18]. Historically, several sPLA<sub>2</sub>s have been detected in mouse and human skin, but by using semi-quantitative RT-PCR and immunoblotting which have uncertain specificity

[19–23]. sPLA<sub>2</sub>s have also been suggested to supply fatty acids for formation of the SC acid mantle, a hypothesis that stems primarily from the observation that SC acidity is perturbed by non-specific sPLA<sub>2</sub> inhibitors [15, 23–25]. However, the molecular identity of any particular sPLA<sub>2</sub>(s) that participates in skin homeostasis and diseases has remained unclear until recently. Now, it has become obvious that sPLA<sub>2</sub>-IIF is a bona fide “epidermal sPLA<sub>2</sub>” that controls keratinocyte differentiation, hyperproliferation, and function [26].

Among the group II subfamily sPLA<sub>2</sub>s (which include sPLA<sub>2</sub>-IIA, sPLA<sub>2</sub>-IIC, sPLA<sub>2</sub>-IID, sPLA<sub>2</sub>-IIE, sPLA<sub>2</sub>-IIF, and sPLA<sub>2</sub>-V), sPLA<sub>2</sub>-IIF has several unique features [27, 28]. sPLA<sub>2</sub>-IIF has a uniquely long C-terminal extension that is proline-rich and contains a single cysteine, which raises the possibility that it might form a covalent homodimer, although this hypothesis has not been confirmed. In contrast to other group II subfamily sPLA<sub>2</sub>s that are basic proteins and catalytically active at neutral to mildly basic pH, sPLA<sub>2</sub>-IIF is an acidic protein (pI ~ 5.8) and retains its full enzymatic activity even at mildly acidic pH. This property may be related to the distribution of this enzyme in the upper epidermis (see below), which has a mildly acidic environment [15]. Furthermore, sPLA<sub>2</sub>-IIF is more hydrophobic than other sPLA<sub>2</sub>s, and probably because of this, it has a unique ability to penetrate and disrupt lipid monolayers and bilayers in vitro; when added exogenously, it rapidly enters the cells in an endocytosis-independent manner to form unusual aggregates [29]. Moreover, when overexpressed, sPLA<sub>2</sub>-IIF also tends to aggregate within the cells and can undergo *N*-glycosylation at three positions, possibly increasing its water solubility and thereby decreasing the unusual accumulation of sPLA<sub>2</sub>-IIF aggregates. However, it remains unknown whether or not endogenous sPLA<sub>2</sub>-IIF (or any other sPLA<sub>2</sub>s) is *N*-glycosylated in vivo. In a PLA<sub>2</sub> enzyme assay using a phospholipid mixture extracted from mouse skin as a substrate (natural membrane assay [30]), a physiologically relevant concentration of sPLA<sub>2</sub>-IIF preferentially hydrolyzes phosphatidylethanolamine (PE; particularly plasmalogen-type PE) containing PUFAs (particularly DHA) to yield plasmalogen-type lysoPE (P-LPE) and DHA in preference to AA [26]. Therefore, although sPLA<sub>2</sub>-IIF is capable of releasing AA when overexpressed in mammalian cells at superphysiological levels [31], it may mobilize lipid metabolites separately from canonical AA metabolism under physiological conditions (see below).

It is now obvious that sPLA<sub>2</sub>-IIF is a major sPLA<sub>2</sub> expressed in mouse epidermis, where it is distributed in the suprabasal SS, SG, and SC layers [26]. Developmental expression of *Pla2g2f* in mouse skin is far greater than that of other sPLA<sub>2</sub>s (except for *Pla2g2e*, see below), gradually increasing before birth to reach a maximum


**Table 1** The classification of PLA<sub>2</sub> family. sPLA<sub>2</sub>, cPLA<sub>2</sub>, and iPLA<sub>2</sub>/PNPLA are the original big three among the PLA<sub>2</sub> family. The sPLA<sub>2</sub> family contains 10 catalytically active isoforms (IB, IIA, IIC, IID, IIE, IIF, III, V, X, XIIA) and 1 inactive isoform (XIIB) in mammals. The cPLA<sub>2</sub> family comprises 6 isoforms (α-ζ). The human genome encodes 9 iPLA<sub>2</sub> enzymes. These enzymes are now more generally referred to as PNPLA (1–9). In this review, the biological roles of particular PLA<sub>2</sub>s in the context of skin homeostasis and diseases were described

Family	Isoforms	Gene name	Common name	Alias	Enzyme property
sPLA <sub>2</sub>	11	PLA2G1B	sPLA <sub>2</sub> -IB	Pancreatic sPLA <sub>2</sub>	PLA <sub>2</sub>
		PLA2G2A	sPLA <sub>2</sub> -IIA	Non-pancreatic sPLA <sub>2</sub>	PLA <sub>2</sub>
		PLA2G2C	sPLA <sub>2</sub> -IIC		PLA <sub>2</sub>
		PLA2G2D	sPLA <sub>2</sub> -IID		PLA <sub>2</sub>
		PLA2G2E	sPLA <sub>2</sub> -IIE		PLA <sub>2</sub>
		PLA2G2F	sPLA <sub>2</sub> -IIF		PLA <sub>2</sub>
		PLA2G3	sPLA <sub>2</sub> -III		PLA <sub>2</sub>
		PLA2G5	sPLA <sub>2</sub> -V		PLA <sub>2</sub>
		PLA2G10	sPLA <sub>2</sub> -X		PLA <sub>2</sub>
		PLA2G12A	sPLA <sub>2</sub> -XIIA		PLA <sub>2</sub>
		PLA2G12B	sPLA <sub>2</sub> -XIIB		Inactive
		cPLA <sub>2</sub>	6	PLA2G4A	cPLA <sub>2</sub> α
PLA2G4B	cPLA <sub>2</sub> β				PLA <sub>1</sub> /A <sub>2</sub>
PLA2G4C	cPLA <sub>2</sub> γ				PLA <sub>2</sub> , transacylase, lysopholipase
PLA2G4D	cPLA <sub>2</sub> δ				PLA <sub>1</sub> /A <sub>2</sub>
PLA2G4E	cPLA <sub>2</sub> ε				PLA <sub>1</sub> /A <sub>2</sub> , N-acyltransferase
PLA2G4F	cPLA <sub>2</sub> ζ				PLA <sub>1</sub> /A <sub>2</sub>
iPLA <sub>2</sub> /PNPLA	9	PNPLA1			Transacylase
		PNPLA2	iPLA <sub>2</sub> ζ	ATGL	TG lipase
		PNPLA3	iPLA <sub>2</sub> ε	ADPN	TG lipase, acyltransferase, restiny-esteryl lipase
		PNPLA4	iPLA <sub>2</sub> η	GS2	Retinyl-esteryl lipase?
		PNPLA5		GS2L	TG lipase
		PNPLA6	iPLA <sub>2</sub> δ	NTE	Lysophospholipase
		PNPLA7		NRE	Lysophospholipase
		PNPLA8	iPLA <sub>2</sub> γ		PLA <sub>1</sub> /A <sub>2</sub>
		PNPLA6	iPLA <sub>2</sub> β	PNPLA9	PLA <sub>2</sub>

level by P5 (Fig. 2a). sPLA<sub>2</sub>-IIF expression is markedly induced during Ca<sup>2+</sup>-induced differentiation and also robustly upregulated in primary keratinocytes following stimulation with the Th17 cytokines IL-22 and IL-17A. Moreover, sPLA<sub>2</sub>-IIF is induced in mouse skin treated with imiquiod, an inducer of experimental psoriasis, and also highly expressed in the hyperplastic epidermis of patients with psoriasis. Strikingly, global or skin-specific transgenic mice overexpressing mouse sPLA<sub>2</sub>-IIF (*Pla2g2f*-TG) spontaneously develop psoriasis-like epidermal hyperplasia and alopecia, with increased expression of various psoriasis markers such as S100A9 and IL-36α [26], suggesting that increased expression of this sPLA<sub>2</sub> alone could trigger psoriasis.

In a basal state, *Pla2g2f*<sup>-/-</sup> mice have mild abnormalities in the skin (particularly the abdominal skin, probably because it is continuously exposed to friction against the

ground surface), as revealed by a fragile stratum corneum with modest perturbation of skin barrier function and acidity [26]. After tape stripping of the SC, *Pla2g2f*<sup>-/-</sup> mice display delayed recovery from the epidermal barrier perturbation [23]. In primary culture, keratinocytes from *Pla2g2f*<sup>-/-</sup> mice fail to differentiate and become properly activated (Fig. 2b), and similar defects are evident when WT keratinocytes are treated with a pan-sPLA<sub>2</sub> inhibitor or an sPLA<sub>2</sub>-IIF-directed siRNA. Most importantly, in pathological settings, *Pla2g2f*<sup>-/-</sup> mice are protected from epidermal hyperplasia and associated inflammation in models of Th17-dependent psoriasis and Th1-dependent contact hypersensitivity (CHS) [26]. Consistent with this, *Pla2g2f* deficiency in keratinocytes markedly impairs the induction of several psoriasis markers in response to IL-17A or IL-22. Moreover, *Pla2g2f*<sup>-/-</sup> mice are also protected from skin carcinogenesis,



**Fig. 1** Expressions and functions of various PLA<sub>2</sub>s in mouse skin. sPLA<sub>2</sub>-IIF is localized in the suprabasal epidermis and produces P-LPE, which promotes epidermal hyperplastic diseases such as psoriasis and skin cancer. Epidermal sPLA<sub>2</sub>-IIF expression and thereby P-LPE production are augmented by IL-17A and IL-22 supplied by γδ T and Th17 cells in psoriasis. sPLA<sub>2</sub>-IIE is localized in hair follicles in synchrony with the growing phase (anagen) of hair cycling and may regulate hair homeostasis. sPLA<sub>2</sub>-IID is constitutively expressed in DCs and M2 macrophages in regional LNs and produces ω<sub>3</sub> PUFA-derived anti-inflammatory lipid mediators, which put a brake on Th1 or Th17 immunity, thereby sequestering CHS and psoriasis and promoting skin cancer. PNPLA1 is expressed in the border of SG and SC, where it produces ω-O-acylceramide that is essential for skin barrier function. For details, please see the text


whereas *Pla2g2f*-TG mice conversely develop larger skin tumors than WT mice [26]. Mechanistically, sPLA<sub>2</sub>-IIF preferentially hydrolyzes plasmalogen-type PE secreted from keratinocytes to yield P-LPE, a unique lysophospholipid that facilitates the differentiation and activation of keratinocytes, leading to exacerbation of epidermal hyperplasia and inflammation. Indeed, the skin levels of P-LPE are correlated well with those of sPLA<sub>2</sub>-IIF expression in several skin disease models, and topical application of P-LPE to *Pla2g2f*<sup>-/-</sup> skin in vivo or supplementation of *Pla2g2f*<sup>-/-</sup> keratinocytes with P-LPE ex vivo restores the psoriasis-related phenotypes.

Taken together, these results indicate that sPLA<sub>2</sub>-IIF promotes epidermal hyperplastic diseases including psoriasis and skin cancer and that P-LPE, a primary sPLA<sub>2</sub>-IIF product, represents a biomarker and bioactive lipid that reflects the expression and function of sPLA<sub>2</sub>-IIF. Given that sPLA<sub>2</sub>-IIF is expressed in the epidermis rather specifically and that *Pla2g2f*<sup>-/-</sup> mice display more profound skin phenotypes in diseases than in homeostasis, inhibition of this particular sPLA<sub>2</sub> may be useful for treatment of psoriasis, skin cancer, or other conditions involving epidermal hyperplasia. It remains to be determined, however, whether sPLA<sub>2</sub>-IIF-driven P-LPE would

act on keratinocytes through a specific receptor or through other mechanism(s). It is also possible that DHA, another sPLA<sub>2</sub>-IIF-driven product, would be metabolized to certain metabolites that could affect skin homeostasis, since DHA or its pro-resolving metabolites can facilitate skin wound healing, suppress psoriasis, and prevent neoplastic transformation of keratinocytes [32–34].

### sPLA<sub>2</sub>-IIE, a hair follicular sPLA<sub>2</sub>

Although sPLA<sub>2</sub>-IIE is not substantially expressed in the epidermis, it is a major “hair follicular sPLA<sub>2</sub>” in mice, being expressed in hair follicles in synchrony with hair cycling [35]. Thus, during the anagen phase, sPLA<sub>2</sub>-IIE is distributed in companion cells of the outer root sheath and cuticular cells of the inner root sheath in growing hair follicles. At P10–15, when hair follicles are maximally developed in the initial hair cycle, the expression of sPLA<sub>2</sub>-IIE becomes maximal, even exceeding that of sPLA<sub>2</sub>-IIF in the whole mouse skin (Fig. 2a). In contrast, during the catagen to telogen phase, when hair follicles regress, sPLA<sub>2</sub>-IIE expression promptly decreases to a negligible level, and then rises again in correlation with entry into the next anagen.



**Fig. 2** Skin abnormalities in knockout and transgenic mice for various sPLA<sub>2</sub>s. **a** Developmental expression of sPLA<sub>2</sub>s in mouse skin as assessed by quantitative RT-PCR. *Pla2g2f* is expressed throughout the peri- to postnatal period, while the periodic pattern of *Pla2g2e* expression coincides with the hair cycle, which involves repeated cycles of growth (anagen; P0–15), regression (catagen; P15–20), rest (telogen; P20–25), and re-growth (the next anagen; beyond P25). A representative result of two independent experiments is shown. **b** Expression of several keratinocyte markers in *Pla2g2f*<sup>+/+</sup> and *Pla2g2f*<sup>-/-</sup> keratinocytes cultured for the indicated periods with 1 mM Ca<sup>2+</sup> ( $n = 4$ , mean  $\pm$  SEM, \* $P < 0.05$ ). *Pla2g2f* deficiency impairs the induction of *S100a9* (an activation marker) and *Krt1* (an SS marker), but not *Krt14* (a SB marker), suggesting that sPLA<sub>2</sub>-IIF regulates keratinocyte differentiation and activation. **c** Microarray profiling (Agilent Technologies) of genes associated with hair follicles and epidermis in *Pla2g2f*-TG (IIF-TG) or *PLA2G10*-TG (X-TG) mice relative to WT mice. In both strains, similar sets of genes are decreased in hair follicles (green), which reflects alopecia, and increased in the epidermis (red), which reflects epidermal hyperplasia. **d** Hematoxylin and eosin staining of skins from WT and *PLA2G10*-TG mice at P25. Hair follicle distortion and epidermal thickening are evident in the TG mice. IRS, inner root sheath. All animal experiments were performed in accordance with the protocols approved by the Institutional Animal Care and Use Committees in accordance with the Japanese Guide for the Care and Use of Laboratory Animals

*Pla2g2e*<sup>-/-</sup> mice exhibit mild skin abnormalities with perturbation of hair follicle ultrastructure and modest changes in the steady-state expression of a subset of skin genes. Lipidomics analysis has revealed that sPLA<sub>2</sub>-IIE mobilizes various unsaturated fatty acids and LPE species (both acyl and plasmalogen forms) in mouse skin, in agreement with the in vitro substrate selectivity of this enzyme [35]. Although several lipid mediators such as PGD<sub>2</sub> and LPA play crucial roles in hair homeostasis [13, 36], the hair phenotypes observed in mice lacking sPLA<sub>2</sub>-IIE appear to be much milder than those in mice lacking synthases or receptors for these lipid mediators. Therefore, it still remains unclear which lipid metabolites mobilized by sPLA<sub>2</sub>-IIE are involved in the regulation of hair follicle homeostasis. Notably, in contrast to *Pla2g2f*<sup>-/-</sup> mice, *Pla2g2e*<sup>-/-</sup> mice do not exhibit psoriasis-related phenotypes [35], implying that these two skin sPLA<sub>2</sub>s—hair follicular sPLA<sub>2</sub>-IIE and epidermal sPLA<sub>2</sub>-IIF—play non-redundant roles in distinct compartments of mouse skin, underscoring the functional diversity of

multiple sPLA<sub>2</sub>s in the coordinated regulation of skin homeostasis and diseases.

Since humans are essentially furless, it is unclear whether sPLA<sub>2</sub>-IIE is also expressed and plays certain roles in human hair follicles. It should be noted that although sPLA<sub>2</sub>-IIE expression is induced in several mouse tissues during inflammation [37], it is hardly detected in human tissues, representing a notable species difference. As sPLA<sub>2</sub>-IIA, the closest homolog of sPLA<sub>2</sub>-IIE, is highly induced during inflammation in humans [37], it has been proposed that the functions of sPLA<sub>2</sub>-IIA in humans might be compensated by sPLA<sub>2</sub>-IIE in mice [38].

### sPLA<sub>2</sub>-IID, a resolving sPLA<sub>2</sub>

While sPLA<sub>2</sub>-IIF and sPLA<sub>2</sub>-IIE are abundantly expressed in keratinocytes of the upper epidermis and hair follicles, respectively (see above), sPLA<sub>2</sub>-IID is barely detectable in mouse skin. Instead, sPLA<sub>2</sub>-IID is abundantly expressed in dendritic cells (DCs) and M2-like macrophages in

secondary lymphoid organs such as the spleen and lymph nodes (LNs) of mice and humans [39, 40]. The expression of sPLA<sub>2</sub>-IID is downregulated, rather than upregulated, following inflammatory stimuli [39, 41]. This property is unique among the sPLA<sub>2</sub> isoforms and probably reflects its role as a “resolving sPLA<sub>2</sub>” that counteracts inflammation [18, 39]. Despite the low expression of sPLA<sub>2</sub>-IID in skin, *Pla2g2d* deficiency leads to exacerbation of CHS and psoriasis. This is most likely because sPLA<sub>2</sub>-IID attenuates adaptive immunity in the LNs, thereby sequestering Th1 and Th17 immune responses [39, 40].

In a model of CHS, the resolution of inflammation in the skin and regional LNs is delayed in *Pla2g2d*<sup>-/-</sup> mice [39]. In this state, expression of the Th1 cytokines IFN- $\gamma$  and IL-12 is robustly elevated in the LNs. Likewise, in a model of psoriasis, *Pla2g2d*<sup>-/-</sup> mice display more severe epidermal hyperplasia than do *Pla2g2d*<sup>+/+</sup> mice, with increased IL-17A<sup>+</sup> or IL-22<sup>+</sup> T cells in the affected skin and LNs [40]. Furthermore, DCs isolated from *Pla2g2d*<sup>-/-</sup> mice are hyper-activated even in the absence of stimulation. Mechanistically, sPLA<sub>2</sub>-IID in the LNs constitutively hydrolyzes PUFA-containing PE species (likely in microparticle membranes) to mobilize  $\omega$ 3 PUFA-derived anti-inflammatory lipid mediators, which can put a brake on DC-committed adaptive immunity. Indeed, the steady-state levels of  $\omega$ 3 PUFAs and their metabolites, such as DHA-derived resolvin D1 (RvD1), are markedly reduced in the LNs of *Pla2g2d*<sup>-/-</sup> mice relative to *Pla2g2d*<sup>+/+</sup> mice. Conversely, *Pla2g2d*-TG mice display milder inflammation in the CHS and psoriasis models, with increased levels of  $\omega$ 3 PUFA metabolites [40].  $\omega$ 3 PUFA-derived resolvins and maresins suppress acquired immunity by attenuating migration and activation of DCs, antigen presentation to T cells, and IgE class switching in B cells [10, 39, 42, 43]. Moreover, these  $\omega$ 3 PUFA-derived lipid mediators have the ability to facilitate the polarization of anti-inflammatory M2 macrophages [44, 45], consistent with the fact that fewer M2 macrophages are present in the LNs of *Pla2g2d*<sup>-/-</sup> mice [40].


On the other hand, the beneficial role of sPLA<sub>2</sub>-IID in counteracting harmful Th1/Th17 immune responses can be conversely disadvantageous in some situations such as host defense against infection and cancer [40, 46]. Indeed, sPLA<sub>2</sub>-IID promotes, rather than prevents, the development of skin tumors, likely because it attenuates anti-tumor Th1 immunity. Accordingly, *Pla2g2d*<sup>-/-</sup> mice are protected against skin carcinogenesis, with increased numbers of tumor-suppressing cytotoxic T cells and M1 macrophages [40]. Thus, the immunosuppressive function of sPLA<sub>2</sub>-IID provides “good” or “bad” outcomes in distinct disease settings, protecting against skin inflammation and exacerbating skin cancer. In the latter context, specific inhibition of sPLA<sub>2</sub>-IID in patients with

certain types of cancer would be a potentially attractive therapeutic intervention for restoration of immunological functions, a concept reminiscent of “immune checkpoint” therapy.

### Recalling sPLA<sub>2</sub>-IIA and sPLA<sub>2</sub>-X: a matter of species difference

As in the case of transgenic mice overexpressing sPLA<sub>2</sub>-IIF [26], those overexpressing human sPLA<sub>2</sub>-IIA or sPLA<sub>2</sub>-X (*PLA2G2A*-TG and *PLA2G10*-TG, respectively) also develop alopecia and epidermal hyperplasia, accompanied by cyst formation, sebaceous gland hyperplasia, and a disturbed hair stem cell fate (Fig. 2c, d) [47–49]. However, since neither sPLA<sub>2</sub>-IIA nor sPLA<sub>2</sub>-X is endogenously detected in mouse skin at a substantial level [26, 50], the intrinsic roles of these two sPLA<sub>2</sub>s in the skin have remained elusive. The discovery of sPLA<sub>2</sub>-IIF as a bona fide “epidermal sPLA<sub>2</sub>” in mice [26] has led to speculation that the skin phenotypes observed in *PLA2G2A*-TG or *PLA2G10*-TG mice may reflect the fact that sPLA<sub>2</sub>-IIA or sPLA<sub>2</sub>-X mimics the intrinsic actions of sPLA<sub>2</sub>-IIF when artificially overexpressed in the skin, or that endogenous sPLA<sub>2</sub>-IIF is upregulated in the hyperplastic epidermis of these transgenic mice. In support of the latter idea, the skin of *PLA2G10*-TG mice has elevated expression of sPLA<sub>2</sub>-IIF, with increased hydrolysis of DHA-containing PE species [26, 49], and microarray gene profiling of the skin reveals similar changes in gene expression between *PLA2G2F*-TG and *PLA2G10*-TG mice (Fig. 2c).

However, considering the species difference between mice and humans, as already pointed out for the relationship between sPLA<sub>2</sub>-IIA and sPLA<sub>2</sub>-IIE (see above), it seems important to reconcile the expression of sPLA<sub>2</sub>-IIA or sPLA<sub>2</sub>-X in human keratinocytes. Indeed, beyond the uncertainty regarding the specificity of the detection methods employed, previous studies have demonstrated the expression of various sPLA<sub>2</sub>s in human keratinocytes [21]. Moreover, under the assumption that sPLA<sub>2</sub>-X is expressed in keratinocytes, exogenously added sPLA<sub>2</sub>-X can stimulate dendricity and pigmentation of human melanocytes through a mechanism dependent upon lysophosphatidylcholine [51]. We therefore reevaluated the expression of sPLA<sub>2</sub>s in human keratinocytes by quantitative RT-PCR. As in mouse primary epidermal keratinocytes (MPEKs) (Fig. 3a), *PLA2G2F* was induced following Ca<sup>2+</sup>-induced differentiation, whereas other sPLA<sub>2</sub>s including *PLA2G1B*, *PLA2G2A*, *PLA2G2D*, *PLA2G2E*, *PLA2G5*, and *PLA2G10* were barely detectable, in human primary epidermal keratinocytes (HPEKs) (Fig. 3b). In contrast, in the transformed human keratinocyte cell line HaCaT, there was robust Ca<sup>2+</sup>-induced up-regulation of *PLA2G2A* and *PLA2G10*, which was even greater than that of *PLA2G2F* as well as *PLA2G5* (Fig. 3c).



These results suggest that not only sPLA<sub>2</sub>-IIF, but also sPLA<sub>2</sub>-IIA, sPLA<sub>2</sub>-X, and possibly sPLA<sub>2</sub>-V can be expressed in transformed, rather than normal, human keratinocytes. Thus, although it is possible that sPLA<sub>2</sub>-IIA and sPLA<sub>2</sub>-X might participate in certain forms of skin pathology such as cancer, it is nonetheless likely that sPLA<sub>2</sub>-IIF is the primary sPLA<sub>2</sub> acting in the epidermis of both mice and humans under physiological conditions. This is reminiscent of the fact that sPLA<sub>2</sub>-V is upregulated in the transformed mouse macrophage cell line P388D<sub>1</sub> [52], whereas it is not induced, but rather downregulated, in primary mouse macrophages [38], after stimulation with LPS or zymosan. Therefore, caution should be exercised when interpreting the data obtained from studies using transformed cell lines.

### PNPLA1, an ω-O-acylceramide synthase (transacylase)

The epidermis contains a unique class of ceramides with ω-hydroxy ultra-long chain fatty acids (C30–C36) esterified

specifically with LA. This particular ceramide class is called ω-O-acylceramide, a key lipid component essential for skin barrier function [53]. The unique structure and high hydrophobicity of ω-O-acylceramide are important for the organization and function of lipid lamellae in the SC, where this unique lipid serves as a “molecular rivet” that connects adjacent lamellar membrane structures. ω-O-acylceramide also acts as a precursor of protein-bound ceramides for formation of the cornified lipid envelope, where a lipid monolayer is covalently bound to the cornified envelope. A series of recent studies on patients with congenital ichthyosis have revealed that many of the causal genes are related to the biosynthesis and metabolism of ω-O-acylceramide [54]. The entire picture of ω-O-acylceramide metabolism has been comprehensively summarized in other recent reviews [14, 55].

A recent breakthrough in this research area has been the identification of PNPLA1, a member of the iPLA<sub>2</sub> family, as a long-sought ω-O-acylceramide synthase, whose genetic mutations in humans and dogs cause congenital

ichthyosis [56] and deletion in mice leads to neonatal death due to excessive transepidermal dehydration resulting from severe skin barrier defect [57–59]. PNPLA1 catalyzes the unique transacylase reaction, whereby the LA moiety cleaved from triacylglycerol through the lipase-like reaction of this enzyme is directly transferred to the  $\omega$ -hydroxy moiety of ultra-long chain fatty acid in ceramide ( $\omega$ -*O*-hydroxyceramide), with the  $\omega$ -hydroxy group, instead of water, serving as an acyl (linoleoyl) acceptor [60]. Thus, on the basis of PLA<sub>2</sub> biology, PNPLA1 is particularly unique in that it (i) is involved in the metabolism of sphingolipids rather than glycerophospholipids, (ii) catalyzes transacylation rather than hydrolysis of target substrates, and (iii) recognizes the specific lipoquality of LA and ultra-long chain fatty acids.

Of additional note, PLA2G15 (also known as lysosomal PLA<sub>2</sub> or LPLA2) has the capacity to catalyze the biosynthesis of 1-*O*-acylceramide through transacylation of fatty acid from the *sn*-2 position of phospholipid to the 1-hydroxy group of ceramide [61]. 1-*O*-acylceramide is a natural component of human and mouse epidermis [62]. However, the biological importance of this unique lipid and the contribution of PLA2G15 to its biosynthesis *in vivo* are unclear.

## Conclusions

Healthy skin depends on a unique lipid profile to form a barrier that confers protection and prevents excessive water loss, aids cell-cell communication, and regulates cutaneous homeostasis and inflammation. Alterations in the cutaneous lipid profile often have severe consequences for skin health and have been implicated in various skin diseases. Recent developments in lipidomics technologies now allow in-depth qualitative and quantitative investigation of a wide variety of cutaneous lipids, providing insight into their roles and mechanistic actions [63]. Cross-communication between various types of bioactive lipids suggests that their cutaneous activities should be considered as part of a wider metabolic network that can be targeted to maintain skin health, control inflammation, and improve skin pathologies [64].

Given that PLA<sub>2</sub>s are crucial enzymes for the control of lipoquality, it is of particular importance to understand the expression and function of each PLA<sub>2</sub> in a specific skin niche. In addition to sPLA<sub>2</sub>s and PNPLA1, which we have focused on here, several biochemical and pharmacological studies have suggested potential contributions of other PLA<sub>2</sub>s such as cytosolic PLA<sub>2</sub>s (cPLA<sub>2</sub> $\alpha$  and cPLA<sub>2</sub> $\delta$ ) to skin inflammation [65–68], although these findings should be confirmed by genetic studies using knockout mice for these enzymes. Our preliminary study has revealed that several other PLA<sub>2</sub>s are also expressed in different cell populations and may play distinct roles in skin homeostasis and inflammation. Thus,

unveiling the entire view of lipid metabolism driven by various forms of PLA<sub>2</sub>s will support translational studies exploring the involvement of lipids in skin health and disease.

## Abbreviations

AA: Arachidonic acid; CHS: Contact hypersensitivity; DC: Dendritic cells; DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid; HPEKs: Human primary epidermal keratinocytes; iPLA<sub>2</sub>: Ca<sup>2+</sup>-independent phospholipase A<sub>2</sub>; LA: Linoleic acid; LN: Lymph nodes; LPA: Lysophosphatidic acid; LT: Leukotriene; MPEKs: Mouse primary epidermal keratinocytes; PE: Phosphatidylethanolamine; PG: Prostaglandin; P-LPE: Plasmalogen-type lysoPE; PNPLA: Patatin-like phospholipase; PUFA: Polyunsaturated fatty acid; Rv: Resolvin; SB: Stratum basale; SC: Stratum corneum; SG: Stratum granulosum; sPLA<sub>2</sub>: Secreted phospholipase A<sub>2</sub>; SS: Stratum spinosum

## Acknowledgements

We thank all the lab members and collaborators who contributed to this work.

## Funding

This work was supported by JSPS KAKENHI Grant Numbers JP18K06624 (to Y.T.), JP15H05905, JP16H02613, and JP18H05025 (to M.M.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and AMED-CREST gm0710006h9906 (to M.M.) and PRIME gm5910012 (to K.Y.) from the Japan Agency for Medical Research and Development.

## Availability of data and materials

All data generated or analyzed during this study are included in this published article.

## Authors' contributions

MM and YT wrote the manuscript. KY and YT performed the experiments in Figs. 2 and 3, respectively. All authors read and approved the final manuscript.

## Ethics approval and consent to participate

Not applicable.

## Consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Author details

<sup>1</sup>Laboratory of Microenvironmental and Metabolic Health Science, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

<sup>2</sup>AMED-CREST, Japan Agency for Medical Research and Development, 1-7-1

Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan. <sup>3</sup>PRIME, Japan Agency for

Medical Research and Development, 1-7-1 Otemachi, Chiyoda-ku, Tokyo

100-0004, Japan. <sup>4</sup>Division of Bioscience and Bioindustry, Graduate School of Technology, Industrial and Social Sciences, Tokushima University, Tokushima 770-8513, Japan.

Received: 1 October 2018 Accepted: 21 November 2018

Published online: 07 December 2018

## References

1. Elias PM. The skin barrier as an innate immune element. *Semin Immunopathol.* 2007;29:3–14.
2. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. *Nat Rev Immunol.* 2009;9:679–91. <https://doi.org/10.1038/nri2622>.
3. Elias PM, Williams ML, Holleran WM, Jiang YJ, Schmutz M. Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of

- lipid metabolism. *J Lipid Res.* 2008;49:697–714. <https://doi.org/10.1194/jlr.R800002-JLR200>.
4. Fuchs E. Scratching the surface of skin development. *Nature.* 2007;445:834–42. <https://doi.org/10.1038/nature05659>.
  5. Festa E, Fretz J, Berry R, Schmidt B, Rodeheffer M, Horowitz M, et al. Adipocyte lineage cells contribute to the skin stem cell niche to drive hair cycling. *Cell.* 2011;146:761–71. <https://doi.org/10.1016/j.cell.2011.07.019>.
  6. Plikus MV, Guerrero-Juarez CF, Ito M, Li YR, Dedhia PH, Zheng Y, et al. Regeneration of fat cells from myofibroblasts during wound healing. *Science.* 2017;355:748–52. <https://doi.org/10.1126/science.aai8792>.
  7. Harms M, Seale P. Brown and beige fat: development, function and therapeutic potential. *Nat Med.* 2013;19:1252–63. <https://doi.org/10.1038/nm.3361>.
  8. Kabashima K, Sakata D, Nagamachi M, Miyachi Y, Inaba K, Narumiya S. Prostaglandin E<sub>2</sub>-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. *Nat Med.* 2003;9:744–9. <https://doi.org/10.1038/nm872>.
  9. Liu M, Saeki K, Matsunobu T, Okuno T, Koga T, Sugimoto Y, et al. 12-Hydroxyheptadecatrienoic acid promotes epidermal wound healing by accelerating keratinocyte migration via the BLT2 receptor. *J Exp Med.* 2014;211:1063–78. <https://doi.org/10.1084/jem.20132063>.
  10. Sawada Y, Honda T, Hanakawa S, Nakamizo S, Murata T, Ueharaguchi-Tanada Y, et al. Resolvin E1 inhibits dendritic cell migration in the skin and attenuates contact hypersensitivity responses. *J Exp Med.* 2015;212:1921–30. <https://doi.org/10.1084/jem.20150381>.
  11. Kim SN, Akindehin S, Kwon HJ, Son YH, Saha A, Jung YS, et al. Anti-inflammatory role of 15-lipoxygenase contributes to the maintenance of skin integrity in mice. *Sci Rep.* 2018;8:8856. <https://doi.org/10.1038/s41598-018-27221-7>.
  12. Kazantseva A, Goltsov A, Zinchenko R, Grigorenko AP, Abrukova AV, Moliaka YK, et al. Human hair growth deficiency is linked to a genetic defect in the phospholipase gene *LIPH*. *Science.* 2006;314:982–5. <https://doi.org/10.1126/science.1133276>.
  13. Inoue A, Arima N, Ishiguro J, Prestwich GD, Arai H, Aoki J. LPA-producing enzyme PA-PLA<sub>1</sub>α regulates hair follicle development by modulating EGFR signalling. *EMBO J.* 2011;30:4248–60. <https://doi.org/10.1038/emboj.2011.296>.
  14. Elias PM, Gruber R, Crumrine D, Menon G, Williams ML, Wakefield JS, et al. Formation and functions of the neonocyte lipid envelope (CLE). *Biochim Biophys Acta.* 2014;1841:314–8. <https://doi.org/10.1016/j.bbali.2013.09.011>.
  15. Fluhr JW, Behne MJ, Brown BE, Moskowitz DG, Selden C, Mao-Qiang M, et al. Stratum corneum acidification in neonatal skin: secretory phospholipase A<sub>2</sub> and the sodium/hydrogen antiporter-1 acidify neonatal rat stratum corneum. *J Invest Dermatol.* 2004;122:320–9. <https://doi.org/10.1046/j.0022-202X.2003.00204.x>.
  16. Murakami M, Taketomi Y, Miki Y, Sato H, Hirabayashi T, Yamamoto K. Recent progress in phospholipase A<sub>2</sub> research: from cells to animals to humans. *Prog Lipid Res.* 2011;50:152–92. <https://doi.org/10.1016/j.plipres.2010.12.001>.
  17. Murakami M, Sato H, Miki Y, Yamamoto K, Taketomi Y. A new era of secreted phospholipase A<sub>2</sub>. *J Lipid Res.* 2015;56:1248–61. <https://doi.org/10.1194/jlr.R058123>.
  18. Murakami M, Yamamoto K, Miki Y, Murase R, Sato H, Taketomi Y. The roles of the secreted phospholipase A<sub>2</sub> gene family in immunology. *Adv Immunol.* 2016;132:91–134. <https://doi.org/10.1016/bs.ai.2016.05.001>.
  19. Schadow A, Scholz-Pedretti K, Lambeau G, Gelb MH, Furstemberger G, Pfeilschifter J, et al. Characterization of group X phospholipase A<sub>2</sub> as the major enzyme secreted by human keratinocytes and its regulation by the phorbol ester TPA. *J Invest Dermatol.* 2001;116:31–9. <https://doi.org/10.1046/j.1523-1747.2001.00179.x>.
  20. Gurrieri S, Furstemberger G, Schadow A, Haas U, Singer AG, Ghomashchi F, et al. Differentiation-dependent regulation of secreted phospholipases A<sub>2</sub> in murine epidermis. *J Invest Dermatol.* 2003;121:156–64. <https://doi.org/10.1046/j.1523-1747.2003.12315.x>.
  21. Haas U, Podda M, Behne M, Gurrieri S, Alonso A, Furstemberger G, et al. Characterization and differentiation-dependent regulation of secreted phospholipases A in human keratinocytes and in healthy and psoriatic human skin. *J Invest Dermatol.* 2005;124:204–11. <https://doi.org/10.1111/j.0022-202X.2004.23513.x>.
  22. Sato H, Taketomi Y, Isogai Y, Masuda S, Kobayashi T, Yamamoto K, et al. Group III secreted phospholipase A<sub>2</sub> transgenic mice spontaneously develop inflammation. *Biochem J.* 2009;421:17–27. <https://doi.org/10.1042/BJ20082429>.
  23. Ilic D, Bollinger JM, Gelb M, Mauro TM. sPLA<sub>2</sub> and the epidermal barrier. *Biochim Biophys Acta.* 2014;1841:416–21. <https://doi.org/10.1016/j.bbali.2013.11.002>.
  24. Mao-Qiang M, Jain M, Feingold KR, Elias PM. Secretory phospholipase A<sub>2</sub> activity is required for permeability barrier homeostasis. *J Invest Dermatol.* 1996;106:57–63.
  25. Fluhr JW, Kao J, Jain M, Ahn SK, Feingold KR, Elias PM. Generation of free fatty acids from phospholipids regulates stratum corneum acidification and integrity. *J Invest Dermatol.* 2001;117:44–51. <https://doi.org/10.1046/j.0022-202X.2001.01399.x>.
  26. Yamamoto K, Miki Y, Sato H, Taketomi Y, Nishito Y, Taya C, et al. The role of group IIF-secreted phospholipase A<sub>2</sub> in epidermal homeostasis and hyperplasia. *J Exp Med.* 2015;212:1901–19. <https://doi.org/10.1084/jem.20141904>.
  27. Valentin E, Ghomashchi F, Gelb MH, Lazdunski M, Lambeau G. On the diversity of secreted phospholipases A<sub>2</sub>. Cloning, tissue distribution, and functional expression of two novel mouse group II enzymes. *J Biol Chem.* 1999;274:31195–202.
  28. Valentin E, Singer AG, Ghomashchi F, Lazdunski M, Gelb MH, Lambeau G. Cloning and recombinant expression of human group IIF-secreted phospholipase A<sub>2</sub>. *Biochem Biophys Res Commun.* 2000;279:223–8. <https://doi.org/10.1006/bbrc.2000.3908>.
  29. Wijewickrama GT, Albanese A, Kim YJ, Oh YS, Murray PS, Takayanagi R, et al. Unique membrane interaction mode of group IIF phospholipase A<sub>2</sub>. *J Biol Chem.* 2006;281:32741–54. <https://doi.org/10.1074/jbc.M606311200>.
  30. Yamamoto K, Miki Y, Sato H, Murase R, Taketomi Y, Murakami M. Secreted phospholipase A<sub>2</sub> specificity on natural membrane phospholipids. *Methods Enzymol.* 2017;583:101–17. <https://doi.org/10.1016/bs.mie.2016.09.007>.
  31. Murakami M, Yoshihara K, Shimbara S, Lambeau G, Gelb MH, Singer AG, et al. Cellular arachidonate-releasing function and inflammation-associated expression of group IIF secretory phospholipase A<sub>2</sub>. *J Biol Chem.* 2002;277:19145–55. <https://doi.org/10.1074/jbc.M112385200>.
  32. Nikolakopoulou Z, Nteliopoulos G, Michael-Titus AT, Parkinson EK. Omega-3 polyunsaturated fatty acids selectively inhibit growth in neoplastic oral keratinocytes by differentially activating ERK1/2. *Carcinogenesis.* 2013;34:2716–25. <https://doi.org/10.1093/carcin/bgt257>.
  33. Arantes EL, Dragano N, Ramalho A, Vitorino D, de-Souza GF, Lima MH, et al. Topical docosahexaenoic acid (DHA) accelerates skin wound healing in rats and activates GPR120. *Biol Res Nurs.* 2016;18:411–9. <https://doi.org/10.1177/1099800415621617>.
  34. Xu J, Duan X, Hu F, Poorun D, Liu X, Wang X, et al. Resolvin D1 attenuates imiquimod-induced mice psoriasisiform dermatitis through MAPKs and NF-κB pathways. *J Dermatol Sci.* 2018;89:127–35. <https://doi.org/10.1016/j.jdermsci.2017.10.016>.
  35. Yamamoto K, Miki Y, Sato H, Nishito Y, Gelb MH, Taketomi Y, et al. Expression and function of group IIE phospholipase A<sub>2</sub> in mouse skin. *J Biol Chem.* 2016;291:15602–13. <https://doi.org/10.1074/jbc.M116.734657>.
  36. Garza LA, Liu Y, Yang Z, Alagesan B, Lawson JA, Norberg SM, et al. Prostaglandin D<sub>2</sub> inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. *Sci Transl Med.* 2012. <https://doi.org/10.1126/scitranslmed.3003122>.
  37. Suzuki N, Ishizaki J, Yokota Y, Higashino K, Ono T, Ikeda M, et al. Structures, enzymatic properties, and expression of novel human and mouse secretory phospholipase A<sub>2</sub>s. *J Biol Chem.* 2000;275:5785–93.
  38. Sato H, Taketomi Y, Ushida A, Isogai Y, Kojima T, Hirabayashi T, et al. The adipocyte-inducible secreted phospholipases PLA2G5 and PLA2G2E play distinct roles in obesity. *Cell Metab.* 2014;20:119–32. <https://doi.org/10.1016/j.cmet.2014.05.002>.
  39. Miki Y, Yamamoto K, Taketomi Y, Sato H, Shimo K, Kobayashi T, et al. Lymphoid tissue phospholipase A<sub>2</sub> group IID resolves contact hypersensitivity by driving antiinflammatory lipid mediators. *J Exp Med.* 2013;210:1217–34. <https://doi.org/10.1084/jem.20121887>.
  40. Miki Y, Kidoguchi Y, Sato H, Taketomi Y, Taya C, Murakami K, et al. Dual roles of group IID phospholipase A<sub>2</sub> in inflammation and cancer. *J Biol Chem.* 2016;291:15588–601. <https://doi.org/10.1074/jbc.M116.734624>.
  41. von Allmen CE, Schmitz N, Bauer M, Hinton HJ, Kurrer MO, Buser RB, et al. Secretory phospholipase A<sub>2</sub>-IID is an effector molecule of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells. *Proc Natl Acad Sci U S A.* 2009;106:11673–8. <https://doi.org/10.1073/pnas.0812569106>.
  42. Chirchiu V, Leuti A, Dall’I, Jacobsson A, Battistini L, Maccarrone M, et al. Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are

- critical in modulating T cell responses. *Sci Transl Med.* 2016;8:353ra111. <https://doi.org/10.1126/scitranslmed.aaf7483>.
43. Kim N, Ramon S, Thatcher TH, Woeller CF, Sime PJ, Phipps RP. Specialized proresolving mediators (SPMs) inhibit human B-cell IgE production. *Eur J Immunol.* 2016;46:81–91. <https://doi.org/10.1002/eji.201545673>.
  44. Titos E, Rius B, Gonzalez-Periz A, Lopez-Vicario C, Moran-Salvador E, Martinez-Clemente M, et al. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. *J Immunol.* 2011;187:5408–18. <https://doi.org/10.4049/jimmunol.1100225>.
  45. Dalli J, Zhu M, Vlasenko NA, Deng B, Haeggstrom JZ, Petasis NA, et al. The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A<sub>4</sub> hydrolase (LTA<sub>4</sub>H), and shifts macrophage phenotype. *FASEB J.* 2013;27:2573–83. <https://doi.org/10.1096/fj.13-227728>.
  46. Vijay R, Hua X, Meyerholz DK, Miki Y, Yamamoto K, Gelb M, et al. Critical role of phospholipase A<sub>2</sub> group IID in age-related susceptibility to severe acute respiratory syndrome-CoV infection. *J Exp Med.* 2015;212:1851–68. <https://doi.org/10.1084/jem.20150632>.
  47. Grass DS, Felkner RH, Chiang MY, Wallace RE, Nevalainen TJ, Bennett CF, et al. Expression of human group II PLA<sub>2</sub> in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate. *J Clin Invest.* 1996;97:2233–41. <https://doi.org/10.1172/JCI118664>.
  48. Mulherkar R, Kirtane BM, Ramchandani A, Mansukhani NP, Kannan S, Naresh KN. Expression of enhancing factor/phospholipase A<sub>2</sub> in skin results in abnormal epidermis and increased sensitivity to chemical carcinogenesis. *Oncogene.* 2003;22:1936–44. <https://doi.org/10.1038/sj.onc.1206229>.
  49. Yamamoto K, Taketomi Y, Isogai Y, Miki Y, Sato H, Masuda S, et al. Hair follicular expression and function of group X secreted phospholipase A<sub>2</sub> in mouse skin. *J Biol Chem.* 2011;286:11616–31. <https://doi.org/10.1074/jbc.M110.206714>.
  50. MacPhee M, Chepenik KP, Liddell RA, Nelson KK, Siracusa LD, Buchberg AM. The secretory phospholipase A<sub>2</sub> gene is a candidate for the *Mom1* locus, a major modifier of *Apc*<sup>Min</sup>-induced intestinal neoplasia. *Cell.* 1995;81:957–66.
  51. Scott GA, Jacobs SE, Pentland AP. sPLA<sub>2</sub>-X stimulates cutaneous melanocyte dendricity and pigmentation through a lysophosphatidylcholine-dependent mechanism. *J Invest Dermatol.* 2006;126:855–61. <https://doi.org/10.1038/sj.jid.5700180>.
  52. Balboa MA, Balsinde J, Winstead MV, Tischfield JA, Dennis EA. Novel group V phospholipase A<sub>2</sub> involved in arachidonic acid mobilization in murine P388D1 macrophages. *J Biol Chem.* 1996;271:32381–4.
  53. Uchida Y, Holleran WM. Omega-O-acylceramide, a lipid essential for mammalian survival. *J Dermatol Sci.* 2008;51:77–87. <https://doi.org/10.1016/j.jdermsci.2008.01.002>.
  54. Akiyama M. Corneocyte lipid envelope (CLE), the key structure for skin barrier function and ichthyosis pathogenesis. *J Dermatol Sci.* 2017;88:3–9. <https://doi.org/10.1016/j.jdermsci.2017.06.002>.
  55. Kihara A. Synthesis and degradation pathways, functions, and pathology of ceramides and epidermal acylceramides. *Prog Lipid Res.* 2016;63:50–69. <https://doi.org/10.1016/j.plipres.2016.04.001>.
  56. Grall A, Guaguere E, Planchais S, Grond S, Bourrat E, Hausser I, et al. *PNPLA1* mutations cause autosomal recessive congenital ichthyosis in golden retriever dogs and humans. *Nat Genet.* 2012;44:140–7. <https://doi.org/10.1038/ng.1056>.
  57. Grond S, Eichmann TO, Dubrac S, Kolb D, Schmutz M, Fischer J, et al. *PNPLA1* deficiency in mice and humans leads to a defect in the synthesis of omega-O-acylceramides. *J Invest Dermatol.* 2017;137:394–402. <https://doi.org/10.1016/j.jid.2016.08.036>.
  58. Hirabayashi T, Anjo T, Kaneko A, Senoo Y, Shibata A, Takama H, et al. *PNPLA1* has a crucial role in skin barrier function by directing acylceramide biosynthesis. *Nat Commun.* 2017;8:14609. <https://doi.org/10.1038/ncomms14609>.
  59. Pichery M, Huchencq A, Sandhoff R, Severino-Freire M, Zaafouri S, Opalka L, et al. *PNPLA1* defects in patients with autosomal recessive congenital ichthyosis and KO mice sustain *PNPLA1* irreplaceable function in epidermal omega-O-acylceramide synthesis and skin permeability barrier. *Hum Mol Genet.* 2017;26:1787–800. <https://doi.org/10.1093/hmg/ddx079>.
  60. Ohno Y, Kamiyama N, Nakamichi S, Kihara A. *PNPLA1* is a transacylase essential for the generation of the skin barrier lipid  $\omega$ -O-acylceramide. *Nat Commun.* 2017;8:14610. <https://doi.org/10.1038/ncomms14610>.
  61. Hiraoka M, Abe A, Shayman JA. Cloning and characterization of a lysosomal phospholipase A<sub>2</sub>, 1-O-acylceramide synthase. *J Biol Chem.* 2002;277:10090–9. <https://doi.org/10.1074/jbc.M111977200>.
  62. Rabionet M, Bayerle A, Marsching C, Jennemann R, Grone HJ, Yildiz Y, et al. 1-O-acylceramides are natural components of human and mouse epidermis. *J Lipid Res.* 2013;54:3312–21. <https://doi.org/10.1194/jlr.M040097>.
  63. Kendall AC, Koszyzcarek MM, Jones EA, Hart PJ, Towers M, Griffiths CEM, et al. Lipidomics for translational skin research: a primer for the uninitiated. *Exp Dermatol.* 2018;27:721–8. <https://doi.org/10.1111/exd.13558>.
  64. Kiezel-Tsugunova M, Kendall AC, Nicolaou A. Fatty acids and related lipid mediators in the regulation of cutaneous inflammation. *Biochem Soc Trans.* 2018;46:119–29. <https://doi.org/10.1042/BST20160469>.
  65. Yamamoto M, Haruna T, Imura K, Hikita I, Furue Y, Higashino K, et al. Inhibitory effect of a potent and selective cytosolic phospholipase A<sub>2</sub> inhibitor RSC-3388 on skin inflammation in mice. *Pharmacology.* 2008;81:301–11. <https://doi.org/10.1159/000117816>.
  66. Roebrock K, Wolf M, Bovens S, Lehr M, Sunderkotter C. Inhibition of benzalkonium chloride-induced skin inflammation in mice by an indol-1-ylpropan-2-one inhibitor of cytosolic phospholipase A<sub>2</sub> $\alpha$ . *Br J Dermatol.* 2012;166:306–16. <https://doi.org/10.1111/j.1365-2133.2011.10637.x>.
  67. Cheung KL, Jarrett R, Subramaniam S, Salimi M, Gutowska-Owsiak D, Chen YL, et al. Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a. *J Exp Med.* 2016;213:2399–412. <https://doi.org/10.1084/jem.20160258>.
  68. Omland SH, Habicht A, Damsbo P, Wilms J, Johansen B, Gniadecki R. A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A<sub>2</sub> inhibitor, AVX001, in patients with mild to moderate plaque psoriasis. *J Eur Acad Dermatol Venerol.* 2017;31:1161–7. <https://doi.org/10.1111/jdv.14128>.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

